Accelerating Time To Market with Biopharma PLM

An Axendia Market Readiness Assessment Report

While most biopharma companies have complex stage-gate product development, change management and investigation processes, they lack the ability to connect decision loops across the total product lifecycle. In other words, they lack a harmonized, integrated, and closed loop approach to product lifecycle management (PLM).

As a result, they are often unable to easily manage and respond to post-approval issues resulting from product, supplier or process changes as well as customer inquiries, adverse events and regulatory findings. Consequently, there is an inconsistent utilization of post-approval change management to improve products and processes. In addition, as biopharmaceutical companies look for opportunities to accelerate innovation cycles, the management of products across the complete lifecycle to support continuous improvement is a strategic imperative.

A digital biopharma product lifecycle management platform could be the key to success.

To evaluate the availability and maturity of solutions that provide digital product, recipe, and process life cycle management, Axendia conducted a market assessment featuring the following technology and service providers.
Respondents are listed in alphabetical order:

  • Dassault Systèmes
  • Emerson
  • Honeywell
  • NeoPLM
  • QbDVision
  • SAP and Pangaea Solutions
  • Siemens

This report identifies technology and service providers whose vision could support end-to-end biopharma PLM, as well as use cases and real-world ROI based on either proof of concept (POC) or live implementations.

Contact us for your complimentary
preview copy of the report!

Schedule an inquiry with us to learn how to “Accelerate your time to Market with BioPharma PLM”.

The opinions and analysis expressed in this Post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this report is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This report is not intended to endorse any company or product and should not be attributed as such.

Scroll to Top